

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 213/30, A61K 31/44	A1	(11) International Publication Number: WO 95/35282 (43) International Publication Date: 28 December 1995 (28.12.95)
(21) International Application Number: PCT/GB95/01460 (22) International Filing Date: 21 June 1995 (21.06.95) (30) Priority Data: 9412383.3 21 June 1994 (21.06.94) GB (71) Applicant: CELLTECH THERAPEUTICS LIMITED [GB/GB]; 216 Bath Road, Slough, Berkshire SL1 4EN (GB). (72) Inventors: HEAD, John, Clifford; Flat 2A, 8 Claremont Road, Windsor, Berkshire SL4 3AX (GB). WARRELOW, Graham, John; Oakside, 4 Wieland Road, Northwood, Middlesex HA6 3QU (GB). ALEXANDER, Rikki, Peter; 14 Carrington Road, High Wycombe, Bucks HP12 3HY (GB). BOYD, Ewan, Campbell; 30 Ledi Avenue, Tullibody, Clacks FK10 2RZ (GB). (74) Agent: SKAILES, Humphrey, John; Frank B. Dehn & Co., Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report.</i>
(54) Title: (R)-4-(2-(3-CYCLOPENTYLOXY-4-METHOXYPHENYL)-2-PHENYLETHYL) PYRIDINE HYDROGEN SULPHATE SALT AS PDE TYPE IV INHIBITOR (57) Abstract The hydrogen sulphate salt of the selective phosphodiesterase type IV inhibitor (R)-4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]-pyridine hydrogen sulphate salt is described. The salt possesses a number of advantageous chemical and physical characteristics making it particularly suitable for pharmaceutical formulation for use in <i>inter alia</i> the prophylaxis and treatment of asthma.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

(R)-4-(2-(3-CYCLOPENTYLOXY-4-METHOXYPHENYL)-2-PHENYLETHYL) PYRIDINE HYDROGEN SULPHATE SALT AS PDE TYPE IV INHIBITOR.

5 This invention concerns (R)-4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine hydrogen sulphate salt, to processes for its preparation, to pharmaceutical compositions containing it and to its use in medicine.

10 In our International Patent Specification No. WO 94/14742 we describe a series of tri-substituted phenyl derivatives which are potent inhibitors of the phosphodiesterase (PDE) type IV isoenzyme at concentrations at which they have little or no inhibitory action on other PDE isoenzymes. The compounds are of use in medicine, especially in the prophylaxis and
15 treatment of asthma.

A particularly useful member of the series is (R)-4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine, hereinafter also referred to as CT1730. In WO 94/14742 we describe the production of CT1730 as the
20 free base [Example 16 (i)] and generally disclose salts of the compound. The production of the racemate is also described [Example 3a)], together with the production of the corresponding hydrochloride salt.

For the use in medicine of a compound such as CT1730 it is essential that
25 a form is available which has appropriate chemical and physical characteristics which enable the easy preparation of stable pharmaceutical formulations. The free base form of CT1730 is unsuitable for this purpose, but we have now found a particular salt form of the compound which has advantageous chemical and physical characteristics. The salt is
30 particularly suitable for pharmaceutical formulation, especially when compared to other salt forms of CT1730.

Thus according to one aspect of the invention we provide (R)-4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine hydrogen
35 sulphate salt.

The hydrogen sulphate salt of the invention possesses a number of advantageous chemical and physical characteristics. In particular, it is (1) highly crystalline; (2) thermally stable; (3) non-hygroscopic, and (4) soluble in aqueous solutions over a wide range of concentrations. In addition, it is readily prepared free of solvent and other impurities.

All of these properties provide the salt of the invention with easy preparation, handling, purity and stability characteristics which make it a particularly suitable form for pharmaceutical formulation. In contrast, other salt forms of CT1730, particularly the hydrochloride, hydrobromide, hydroiodide, methanesulphonate, p-toluenesulphonate, besylate, phosphate, sulphate, nitrate, maleate and fumarate, lack one or more of these properties and are unsuitable for formulation.

The salt according to the invention may be prepared from the corresponding CT1730 free base or a salt thereof. Thus, according to a further aspect of the invention, we provide a process for the preparation of (R)-4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine hydrogen sulphate salt which comprises reacting (R)-4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine or a salt thereof with sulphuric acid.

The reaction may be performed in any suitable solvent or mixtures of solvents. Particular solvents include alcohols, such as ethanol or isopropyl alcohol, and aromatic hydrocarbons such as benzene and toluene. In general, the reaction may be performed at around ambient temperature or above, for example up to around 50°C.

In this reaction, the starting material is preferably the free base. However another salt may be used, or if desired a mixture of the free base and the other salt.

The free base or salt starting materials for this reaction may be prepared by the methods described in International Patent Specification No. WO 94.14742, or in our International Patent Application No. PCT/GB

94/02799. In these applications the free base is described as above or as (+)-4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine.

5 The salt according to the invention is a selective and potent inhibitor of PDE IV. The ability of the compound to act in this way may be simply determined by the tests described in the Examples hereinafter.

10 The salt according to the invention is thus of particular use in the prophylaxis and treatment of human diseases where an unwanted inflammatory response or muscular spasm (for example bladder or alimentary smooth muscle spasm) is present and where the elevation of cAMP levels may be expected to prevent or alleviate the inflammation and relax muscle.

15 Particular uses to which the salt of the invention may be put include the prophylaxis and treatment of asthma, especially inflamed lung associated with asthma, cystic fibrosis, or in the treatment of inflammatory airway disease, chronic bronchitis, eosinophilic granuloma, psoriasis and other benign and malignant proliferative skin diseases, endotoxic shock, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and brain, inflammatory arthritis, chronic glomerulonephritis, atopic dermatitis, urticaria, adult respiratory distress syndrome, diabetes insipidus, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, arterial restenosis and arteriosclerosis.

25 The salt of the invention also suppresses neurogenic inflammation through elevation of cAMP in sensory neurones. It is, therefore, analgesic, anti-tussive and anti-hyperalgesic in inflammatory diseases associated with irritation and pain.

30 The salt according to the invention may also elevate cAMP in lymphocytes and thereby suppress unwanted lymphocyte activation in immune-based diseases such as rheumatoid arthritis, ankylosing spondylitis, transplant rejection and graft versus host disease.

35

The salt according to the invention have also been found to reduce gastric acid secretion and therefore can be used to treat conditions associated with hypersecretion.

- 5 The salt of the invention suppresses cytokine synthesis by inflammatory cells in response to immune or infectious stimulation. It is, therefore, useful in the treatment of bacterial, fungal or viral induced sepsis and septic shock in which cytokines such as tumour necrosis factor (TNF) are key mediators. Also the salt of the invention suppresses inflammation and
10 pyrexia due to cytokines and is, therefore, useful in the treatment of inflammation and cytokine-mediated chronic tissue degeneration which occurs in diseases such as rheumatoid or osteo-arthritis.

- Over-production of cytokines such as TNF in bacterial, fungal or viral
15 infections or in diseases such as cancer, leads to cachexia and muscle wasting. The salt of the invention ameliorates these symptoms with a consequent enhancement of quality of life.

- The salt of the invention also elevates cAMP in certain areas of the brain
20 and thereby counteract depression and memory impairment.

- The salt of the invention suppresses cell proliferation in certain tumour cells and can be used, therefore, to prevent tumour growth and invasion of normal tissues.

- 25 For the prophylaxis or treatment of disease the salt according to the invention is particularly suitable for formulation as a pharmaceutical composition. Thus according to a further aspect of the invention we provide a pharmaceutical composition which comprises (R)-4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine hydrogen
30 sulphate salt together with one or more pharmaceutically acceptable carriers, excipients or diluents.

- Pharmaceutical compositions according to the invention may take a form
35- suitable for oral, buccal, parenteral, nasal, topical or rectal administration, or a form suitable for administration by inhalation or insufflation.

Advantageously, the compositions may be prepared using conventional procedures and thus the invention further provides a process for the preparation of a pharmaceutical composition containing (R)-4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine hydrogen sulphate salt together with one or more pharmaceutically acceptable carriers, excipients or diluents which comprises the step or steps of bringing into contact (R)-4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine hydrogen sulphate salt with one or more pharmaceutically acceptable carriers, excipients or diluents

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets, lozenges or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous vehicles and preservatives. The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.

Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

The salt according to the invention may be formulated for parenteral administration by injection e.g. by bolus injection or infusion. Formulations

for injection may be presented in unit dosage form, e.g. in glass ampoule or multi dose containers, e.g. glass vials. The compositions for injection may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising, preserving and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.

In addition to the formulations described above, the salt according to the invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation or by intramuscular injection.

For nasal administration or administration by inhalation, the salt according to the present invention is conveniently delivered in the form of an aerosol spray presentation for pressurised packs or a nebuliser, with the use of suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.

The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack or dispensing device may be accompanied by instructions for administration.

The quantity of the salt of the invention required for the prophylaxis or treatment of a particular inflammatory condition will vary depending on the condition of the patient to be treated. In general, however, daily dosages may range from around 100ng/kg to 100mg/kg, e.g. around 0.01mg/kg to 40mg/kg body weight for oral or buccal administration, from around 10ng/kg to 50mg/kg body weight for parenteral administration and around 0.05mg to around 1000mg e.g. around 0.5mg to around 1000mg for nasal administration or administration by inhalation or insufflation.

The following Examples illustrate the invention.

EXAMPLE 1**(R)-4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine hydrogen sulphate salt****(R)-4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine**

- 5 (14.5g, 39mmol; prepared as described in International Patent Application No. PCT/GB94/02799 was dissolved in warm ethanol (150ml) and the clear solution then cooled to room temperature. Concentrated sulphuric acid (3.3ml, 60mmol) was added with swirling over one minute, followed by a few seed crystals. The solution was allowed to stand at room
- 10 temperature for 1.5 hours during which time needle-like crystals steadily developed. The solution was then left at 40°C overnight to maximise yield. The resulting product was warmed to room temperature and the crystalline product was collected by suction filtration with *t*-butylmethyl ether washing. Once sufficiently dry, the product was transferred to a
- 15 vacuum oven and heated *in vacuo* to dryness (65°C, ~0.05mbar, overnight) to afford the title salt as a white crystalline powder (16.2g); m.p. 144-146°C; Found C, 63.72; H, 6.15; N, 2.97. C₂₅H₂₉NO₆S requires C, 63.68; H, 6.20; N, 2.97%.

- 20 The title salt (3.3g) was recrystallised (with slow cooling to room temperature, then leaving at room temperature for 2 hours) from absolute ethanol (~40ml). The resulting white needles were filtered, washed with diethyl ether and dried at 75°C at 0.05mbar overnight.

25 EXAMPLE 2

This example shows the formulation of granules containing (R)-4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine hydrogen sulphate salt (referred to in this example as 'Active Ingredient'):

30

	<u>Unit Quantity</u>	<u>Batch Quantity</u>
Active Ingredient	0.1263mg	0.2210g
Maize Starch BP	112.7mg	197.2g
Purified Water	-	110ml
35 Colloidal silica (Aerosil 200)	1.71mg	2.993g

The granules were used to either fill capsules, or were compressed into tablets.

5 **EXAMPLE 3**

The activity and selectivity of the salt according to the invention was demonstrated in the following tests. In these tests the abbreviation FMLP represents the peptide N-formyl-met-leu-phe.

10 **Isolated Enzyme**

The potency and selectivity of the salt of the invention was determined using distinct PDE isoenzymes as follows:

- 15 i. PDE I, rabbit heart
- ii. PDE II, rabbit heart
- iii. PDE III, rabbit heart, Jurkat cells
- iv. PDE IV, HL60 cells, rabbit brain, rabbit kidney and human recombinant PDE IV
- 20 v. PDE V, rabbit lung, guinea pig lung

20 A gene encoding human PDE IV has been cloned from human monocytes (*Livi, et al., 1990, Molecular and Cellular Biology, 10, 2678*). Using similar procedures we have cloned human PDE IV genes from a number of sources including eosinophils, neutrophils, lymphocytes, monocytes, brain
25 and neuronal tissues. These genes have been transfected into yeast using an inducible vector and various recombinant proteins have been expressed which have the biochemical characteristics of PDE IV (*Beavo and Reifsnyder, 1990, TIPS, 11, 150*). These recombinant enzymes, particularly the human eosinophil recombinant PDE IV, have been used as
30 the basis of a screen for potent, selective PDE IV inhibitors.

The enzymes were purified to isoenzyme homogeneity using standard chromatographic techniques.

35 Phosphodiesterase activity was assayed as follows. The reaction was conducted in 150µl of standard mixture containing (final concentrations):

50mM 2-[[tris(hydroxymethyl)methyl]amino]-1-ethane-sulphonic acid (TES)-NaOH buffer (pH 7.5), 10mM MgCl₂, 0.1μM [³H]-cAMP and vehicle or various concentrations of the test compounds. The reaction was initiated by addition of enzyme and conducted at 30°C for between 5 to 30 mins.

5 The reaction was terminated by addition of 50μl 2% trifluoroacetic acid containing [¹⁴C]-5'AMP for determining recovery of the product. An aliquot of the sample was then applied to a column of neutral alumina and the [³H]-cAMP eluted with 10ml 0.1 TES-NaOH buffer (pH8). The [³H]-5'-AMP product was eluted with 2ml 2M NaOH into a scintillation vial containing

10 10ml of scintillation cocktail. Recovery of [³H]-5'AMP was determined using the [¹⁴C]-5'AMP and all assays were conducted in the linear range of the reaction.

The salt according to the invention causes a concentration-dependent

15 inhibition of recombinant PDE IV at 0.1 - 1000nM with little or no activity against PDE I, II, III or V at concentrations up to 100μM.

2. The Elevation of cAMP in Leukocytes

The effect of the salt of the invention on intracellular cAMP was

20 investigated using human neutrophils or guinea pig eosinophils. Human neutrophils were separated from peripheral blood, incubated with dihydrocytochalasin B and the test compound for 10 min and then stimulated with FMLP. Guinea pig eosinophils were harvested by peritoneal lavage of animals previously treated with intra-

25 peritoneal injections of human serum. Eosinophils were separated from the peritoneal exudate and incubated with isoprenaline and test compound. With both cell types, suspensions were centrifuged at the end of the incubation, the cell pellets were resuspended in buffer and boiled for 10 min prior to measurement of cAMP by specific

30 radioimmunoassay (DuPont).

The salt according to the invention induced a concentration-dependent elevation of cAMP in neutrophils and/or eosinophils at a concentration of 0.1nM.

35

3. Suppression of Leukocyte Function

5 The salt of the invention were investigated for its effects on superoxide generation, chemotaxis and adhesion of neutrophils and eosinophils. Isolated leukocytes were incubated with dihydrocytochalasin B for superoxide generation only and test compound prior to stimulation with FMLP. The salt according to the invention caused a concentration-dependent inhibition of superoxide generation, chemotaxis and adhesion at a concentrationsof 0.1nM.

4. **Adverse Effects**

10 The salt according to the invention is free from adverse effects following repeated overdosage to rats or dogs.

CLAIMS

1. (R)-4-[2-(3-Cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine
hydrogen sulphate salt.
- 5 2. A pharmaceutical composition comprising (R)-4-[2-(3-Cyclo-
pentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine hydrogen
sulphate salt together with one or more pharmaceutically acceptable
carriers, excipients or diluents.
- 10 3. A process for the preparation of (R)-4-[2-(3-cyclopentyloxy-4-
methoxyphenyl)-2-phenylethyl]pyridine hydrogen sulphate salt which
comprises reacting (R)-4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-
phenylethyl]pyridine and/or a salt thereof with sulphuric acid.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 95/01460

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C07D213/30 A61K31/44		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07D A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	WO, A, 94 14742 (CELLTECH LIMITED) 7 July 1994 cited in the application see claims 13, 17; examples 3a, 16i -----	1-3
<input type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : <div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
Date of the actual completion of the international search	Date of mailing of the international search report	
20 September 1995	02.10.95	
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tlx. 31 651 epo nl, Fax (+31-70) 340-3016		Authorized officer Bosma, P

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 95/01460

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9414742	07-07-94	AU-B- 5709294	19-07-94
		CA-A- 2129039	07-07-94
		CN-A- 1092064	14-09-94
		CZ-A- 9402034	15-12-94
		EP-A- 0626939	07-12-94
		FI-A- 943856	22-08-94
		GB-A- 2279075	21-12-94
		JP-T- 7504442	18-05-95
		NO-A- 943091	21-10-94
		PL-A- 304892	09-01-95
